NIAID Antiviral Program for Pandemics (APP)

NIAID Antiviral Program for Pandemics (APP) is sponsored by NIAID. Aims to accelerate the discovery, development, and manufacturing of antiviral medicines.

Help Strengthen the Pipeline of Antiviral Drugs for the Next Pandemic | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.

coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.

Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information Help Strengthen the Pipeline of Antiviral Drugs for the Next Pandemic Funding News Editions: July 17, 2024 See more articles in this edition Through Notice of Special Interest (NOSI): Discovery and Development of Oral Small-Molecule Direct-Acting Antivirals Targeting Viruses of Pandemic Potential , NIAID invites research project grant applications to advance candidate antiviral drugs suitable for widespread use in the community in future outbreaks or pandemics.

Specifically, the NOSI encourages discovery and development of small molecule compounds (molecular weight less than 2 kilodaltons) with activity against viral targets that could be administered orally as monotherapy or in combination with other drugs to treat infections caused by viruses of pandemic potential.

Such research may range from early discovery and lead series optimization to late-stage preclinical development and investigational new drug-enabling profiling.

Example project activities include, but are not limited to: Structure-based design and medicinal chemistry Mechanism of action studies Pharmacology and toxicology We strongly encourage applicants to collaborate with pharmaceutical organizations to access chemical starting points and critical medicinal chemistry, as well as regulatory and drug development expertise.

Incorporating multidisciplinary activities may also be appropriate, depending on the project’s stage of candidate discovery and development.

As for what viruses to target, the NOSI considers viral pathogens from the following RNA virus families within scope: Coronaviruses (activity against multiple coronaviruses, ‘pan-CoV,’ required) Bunyaviruses (Bunyavirales order) You must not focus on other virus families or we will consider your application nonresponsive under this NOSI.

Likewise, the NOSI will not support the following: Approaches that target the host and not the virus. Therapeutics that will require intravenous, intranasal, or other non-oral delivery routes. Antibody or other non-small molecule approaches in which the candidate’s molecular weight exceeds 2 kilodaltons.

Efforts to repurpose or reformulate marketed drugs.

NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed) NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Clinical Trial Not Allowed) Remember, you must list “NOT-AI-24-053” in the Agency Routing Identifier field (Box 4B) of the SF 424 R&R form.

To determine your project’s maximum project period, budget limits, and specific submission deadline, refer to the NOFO through which you choose to apply. Direct questions about the NOSI to our scientific/research contacts for the initiative: Dr. Mindy Davis at mindy. davis@nih.

gov or 301-761-6689 and Dr. Dipanwita Basu at dipanwita. basu@nih. gov or 240-627-3469.

Content last reviewed on July 17, 2024